BioNexus Gene Lab Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Lee Tan

İcra Kurulu Başkanı

US$16.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

Feb 14

CEO

Lee Tan (41 yo)

less than a year

Görev süresi

US$16,000

Tazminat

Mr. Su-Leng Tan, also known as Lee, is CEO & Director of BioNexus Gene Lab Corp. from December 11, 2023 and also serves as its Acting Chief Financial Officer and Secretary. Mr. Tan was Chief Operating Offi...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Su-Leng Tan	CEO, Acting CFO	less than a year	US$16.00k	Veri yok
Chee Yap	Independent Non-Executive Director	2.7yrs	US$3.00k	Veri yok
Muhammad bin Abdul Hamid	Independent Director	less than a year	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BGLC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

BioNexus Gene Lab Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee

BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer

Recent updates

Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee

BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024

Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)

High number of new and inexperienced directors

The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)

BioNexus Gene Lab Corp. announced delayed annual 10-K filing

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

High number of new and inexperienced directors

Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp

BioNexus Gene Lab Corp. announced delayed 10-Q filing

BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)

High number of new and inexperienced directors

BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer

BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer

BioNexus Gene Lab Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)

New minor risk - Shareholder dilution

High number of new and inexperienced directors

BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.

Bionexus Gene Lab Corporation Announces Management Changes

BioNexus Gene Lab Corporation announced delayed annual 10-K filing

BioNexus Gene Lab Corporation announced delayed 10-Q filing

BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş